Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial

類似資料

• Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial
  著者:: Westhovens, René, 等
  出版事項: (2021)
• Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
  著者:: Combe, Bernard, 等
  出版事項: (2021)
• Impact of filgotinib on pain control in the phase 3 FINCH studies
  著者:: Bruno Fautrel, 等
  出版事項: (2024-02-01)
• Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes
  著者:: Genovese, Mark, 等
  出版事項: (2018)
• Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor
  著者:: Namour, Florence, 等
  出版事項: (2018)